Ocugen Chairman and CEO to present at Abu Dhabi Family Office Summit
February 26, 2024 08:30 ET
|
Ocugen
MALVERN, Pa., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST
February 22, 2024 16:05 ET
|
Ocugen
MALVERN, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Ocugen to Present at 2024 BIO CEO & Investor Conference
February 21, 2024 16:05 ET
|
Ocugen
MALVERN, Pa., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024
February 14, 2024 07:30 ET
|
Ocugen
Highlighting updates on OCU400 Phase 3 clinical trial starting early 2024 Featuring thought leaders in gene therapy and OCU400 Phase 1/2 clinical trial patient MALVERN, Pa., Feb. 14, 2024 ...
Ocugen to Present at Pharma Market Research Conference
January 31, 2024 08:00 ET
|
Ocugen
MALVERN, Pa., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board
January 16, 2024 07:30 ET
|
Ocugen
MALVERN, Pa., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen Gains FDA Alignment on Key Aspects of OCU400—Modifier Gene Therapy—Pivotal Phase 3 Study Design
December 21, 2023 06:30 ET
|
Ocugen
MALVERN, Pa., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO Mutations
December 19, 2023 07:30 ET
|
Ocugen
RMAT designation intended to help expedite development of new regenerative medicines MALVERN, Pa., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a...
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
December 13, 2023 07:30 ET
|
Ocugen
MALVERN, Pa., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Ocugen CEO to Present at NobleCon19 – Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
November 29, 2023 07:30 ET
|
Ocugen
MALVERN, Pa., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...